• Crestor Medical Record Review & Outsourcing Services

Crestor (rosuvastatin), is a synthetic lipid-lowering agent for oral administration, which is marketed as by AstraZeneca. It is a class of drugs known as HMG-CoA reductase inhibitors (statins). It slows down the production of cholesterol and reducing the buildup of cholesterol on artery walls as well as increases good cholesterol (HDL), thus helping prevent heart diseases and reduce incidences of heart attacks and strokes. AstraZeneca, the manufacturer of Crestor received its Food and Drug Administration (FDA) approval in 2003. In March 2010, Crestor was approved as a preventive medicine for cholesterol control ( highlighting the special criteria).

This drug is used in combination with exercise and diet to lower cholesterol and triglycerides (types of fat) in the blood and to slow the buildup of plaque (fatty deposits) in the blood vessels.

Crestor use was linked to Rhabdomyolysis which is a rare condition that causes excessive deterioration of muscle tissue. When muscle tissue is broken down, myoglobin is released into the patient's bloodstream. However, excessive myoglobin can cause kidney damage. If left untreated, rhabdomyolysis can cause kidney failure and death.

Serious Alleged Injuries may include:

  • Memory loss
  • Type 2 diabetes
  • Liver damage
  • Muscle pain
  • Rhabdomyolysis that can lead to kidney failure and death

FDA Safety Warnings:

Though Crestor is known as the best-selling statin worldwide, it also caused serious complications such as heart problems, muscle damage, and death. In 2005, the manufacturer of Crestor, Astra-Zeneca made a change in a label stating that the drug can cause serious muscle toxicity - the updated label reflected data from studies indicating that Asian people could be at an increased risk of muscle damage. The new label recommended that Asian patients be started on the 5 mg dose.

  • The FDA announced a label change in March 2012 to alert the patients about the side effects and possible drug interactions linked to this statin.
  • Again, in October 2012, the FDA announced to change Crestor's warning label to make the patients aware of the risk of immune-mediated necrotizing myopathy, an autoimmune myopathy associated with this drug.

Legal Updates:

More than 600 lawsuits have been filed against AstraZeneca, alleging that Crestor can develop Type 2 diabetes in the users as of August 2017.


  • Usage of Crestor and other statins in Pharmacy Records.
  • Duration of Usage
  • Proof of injury and Treatment provided for Injuries

Medical Record Review and claim validation of Crestor case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.



Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...


NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...



CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...


CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...


NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

Rewards & Recognition Program - July 2019
Neural IT organized ‘Rewards & Recognition Program' on July 5, 2019, to motivate employees an
International Yoga Day - Image - Neural IT
International Yoga Day celebrated at Neural IT to bring physical and emotional health for our tea
MTMP April 2019
Neural IT shared presence with Mike Papantonio at the spectacular 3-day conferenc

Latest Tweets